In the last trading session, 1.61 million shares of the Lyra Therapeutics Inc (NASDAQ:LYRA) were traded, and its beta was -0.14. Most recently the company’s share price was $0.20, and it changed around $0.01 or 3.63% from the last close, which brings the market valuation of the company to $13.09M. LYRA currently trades at a discount to its 52-week high of $6.79, offering almost -3295.0% off that amount. The share price’s 52-week low was $0.16, which indicates that the current value has risen by an impressive 20.0% since then. We note from Lyra Therapeutics Inc’s average daily trading volume that its 10-day average is 0.83 million shares, with the 3-month average coming to 1.82 million.
Lyra Therapeutics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 3.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 4 recommended LYRA as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Lyra Therapeutics Inc is expected to report earnings per share of -0.13 for the current quarter.
Lyra Therapeutics Inc (NASDAQ:LYRA) trade information
Instantly LYRA has showed a green trend with a performance of 3.63% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.2064 on recent trading dayincreased the stock’s daily price by 3.1%. The company’s shares are currently down -3.10% year-to-date, but still up 9.11% over the last five days. On the other hand, Lyra Therapeutics Inc (NASDAQ:LYRA) is 2.30% up in the 30-day period. We can see from the shorts that 2.14 million shares have been sold at a short interest cover period of 1.67 day(s).
The consensus price target as assigned by Wall Street analysts is $0.5, which translates to bulls needing to increase their stock price by 60.0% from its current value. Analyst projections state that LYRA is forecast to be at a low of $0.5 and a high of $0.5.
Lyra Therapeutics Inc (LYRA) estimates and forecasts
The year-over-year growth rate is expected to be -2.21%, down from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 206k in revenue for the current quarter. The company’s sales for the same quarters a year ago were 146k and 532k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 41.10%. Forecasts for the next quarter put sales growth at -100.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -21.63%. Lyra Therapeutics Inc earnings are expected to increase by -5.36% in 2025, but the outlook is positive 14.56% per year for the next five years.
LYRA Dividends
Lyra Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Lyra Therapeutics Inc (NASDAQ:LYRA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.60% of Lyra Therapeutics Inc shares, and 59.54% of them are in the hands of institutional investors. The stock currently has a share float of 59.90%. Lyra Therapeutics Inc stock is held by 80.0 institutions, with PERCEPTIVE ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 19.9302% of the shares, which is about 12.76 million shares worth $3.53 million.
CITADEL ADVISORS LLC, with 7.4562% or 4.77 million shares worth $1.32 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Nov 30, 2024. The former held 2.52 shares worth $0.5 million, making up 3.85% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 992.54 shares worth around $0.2 million, which represents about 1.52% of the total shares outstanding.
